版本:
中国

BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN

March 23 Stemline Therapeutics Inc:

* Stemline Therapeutics announces completion of enrollment in stage 3 of the sl-401 pivotal trial in bpdcn

* Stemline Therapeutics Inc - company also reviewed key milestones for sl-401 program over coming year

* Stemline Therapeutics Inc - stemline plans to provide a clinical update on patients enrolled in stages 1 and 2 at a medical conference around mid-year

* Stemline Therapeutics Inc - plans to provide top-line data from stage 3 expected in second half of 2017

* Stemline Therapeutics Inc - plans to continue to enroll both first-line and relapsed/refractory bpdcn patients under current protocol Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐